Clinical Trial Update: Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial update investigating efficacy and safety of alirocumab to prevent early cardiac allograft vasculopathy in recent heart transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy
• Heart Transplant-related Conditions

Drugs mentioned

• alirocumab (alirocumab)

Snippet

Sponsor: Institute for Clinical and Experimental Medicine | Conditions: Cardiac Allograft Vasculopathy | Phase 4 | Status: UNKNOWN